The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
First-line erlotinib in advanced non-small cell lung cancer (NSCLC) carrying an activating EGFR mutation: A multicenter academic phase II study in Caucasian patients (pts) (NCT00339586)—FIELT study group.
J. De Greve
Consultant or Advisory Role - Roche
Research Funding - Roche
J. P. Van Meerbeeck
Consultant or Advisory Role - Roche
J. F. Vansteenkiste
Consultant or Advisory Role - Roche
E. Teugels
No relevant relationships to disclose
C. Geers
No relevant relationships to disclose
A. Meert
No relevant relationships to disclose
P. Vuylsteke
No relevant relationships to disclose
C. N. J. Focan
No relevant relationships to disclose
J. Canon
No relevant relationships to disclose
Y. Humblet
No relevant relationships to disclose
G. J. Berchem
No relevant relationships to disclose
B. Colinet
No relevant relationships to disclose
D. Galdermans
No relevant relationships to disclose
L. Bosquée
No relevant relationships to disclose
C. A. Dooms
No relevant relationships to disclose
L. Decoster
No relevant relationships to disclose
J. Vermeij
No relevant relationships to disclose
A. Dewaele
No relevant relationships to disclose
D. C. C. Schallier
No relevant relationships to disclose